Andrea S Henden

Dr. Andrea S Henden

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2019 in Blood
Verified
Journal Article
Closed access
PDF file
AWAndrew N. Wilkinson
Andrew N. Wilkinson
KCKarshing Chang
Karshing Chang
RKRachel D. Kuns
Rachel D. Kuns
AHAndrea S Henden
Andrea S Henden
SMSimone A. Minnie
Simone A. Minnie
GHGeoffrey R. Hill
Geoffrey R. Hill
Key Points: DCs are the principal source of IL-6 dysregulation after alloSCT. IL-6–dependent GVHD is driven by classical signaling of IL-6R on donor T cells but is regulated by trans signaling.

5 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
AHAndrea S Henden
Andrea S Henden
MKMotoko Koyama
Motoko Koyama
RRRenee J. Robb
Renee J. Robb
AFAdriana Forero
Adriana Forero
RKRachel D. Kuns
Rachel D. Kuns
GHGeoffrey R. Hill
Geoffrey R. Hill
Immunopathology and intestinal stem cell (ISC) loss in the gastrointestinal (GI) tract is the prima facie manifestation of graft-versus-host disease (GVHD) and is responsible for significant mortality after allogeneic bone marrow transplantation (BMT). Approaches to prevent GVHD to date focus on immune suppression. Here, we identify interferon-λ (IFN-λ; interleukin-28 [IL-28]/IL-29) as a key protector of GI GVHD immunopathology, notably within the ISC compartment. Ifnlr1−/− mice displayed exaggerated GI GVHD and mortality independent of Paneth cells and alterations to the microbiome. Ifnlr1−/− intestinal organoid growth was significantly impaired, and targeted Ifnlr1 deficiency exhibited effects intrinsic to recipient Lgr5+ ISCs and natural killer cells. PEGylated recombinant IL-29 (PEG-rIL-29) treatment of naive mice enhanced Lgr5+ ISC numbers and organoid growth independent of both IL-22 and type I IFN and modulated proliferative and apoptosis gene sets in Lgr5+ ISCs. PEG-rIL-29 treatment improved survival, reduced GVHD severity, and enhanced epithelial proliferation and ISC-derived organoid growth after BMT. The preservation of ISC numbers in response to PEG-rIL-29 after BMT occurred both in the presence and absence of IFN-λ–signaling in recipient natural killer cells. IFN-λ is therefore an attractive and rapidly testable approach to prevent ISC loss and immunopathology during GVHD.

4 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
KGKate H. Gartlan
Kate H. Gartlan
MKMotoko Koyama
Motoko Koyama
KLKatie E. Lineburg
Katie E. Lineburg
KCKarshing Chang
Karshing Chang
KEKathleen S. Ensbey
Kathleen S. Ensbey
GHGeoffrey R. Hill
Geoffrey R. Hill
Key Points: GM-CSF is derived from both Th17/Tc17-positive and Th17/Tc17-negative donor lineages after bone marrow transplantation. GM-CSF promotes the accumulation of alloantigen-presenting, migratory donor DCs in the gastrointestinal tract during GVHD.

22 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
AHAndrea S Henden
Andrea S Henden
AVAntiopi Varelias
Antiopi Varelias
JLJustine Leach
Justine Leach
ESElise Sturgeon
Elise Sturgeon
JAJudy Avery
Judy Avery
GHGeoffrey R. Hill
Geoffrey R. Hill
Key Points: Peg-IFNα is tolerated and induces disease response in patients who relapse after allogeneic SCT. Increased pretreatment MAIT and pDC proportions were associated with better progression-free and overall survival after peg-IFNα treatment.

1 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Ping ZhangPing Zhang
Ping Zhang
PFPeter Fleming
Peter Fleming
CAChristopher Andoniou
Christopher Andoniou
OWOlivia G. Waltner
Olivia G. Waltner
SBShruti S. Bhise
Shruti S. Bhise
STSiok-Keen Tey
Siok-Keen Tey
Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell–specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibited CMV reactivation. Deletion of IFN-γ in donor T cells also eliminated EC injury and FcRn loss. In a phase III clinical trial, blockade of IL-6R with tocilizumab promoted CMV-specific IgG persistence and significantly attenuated early HCMV reactivation. In sum, IL-6 invoked IFN-γ–dependent EC injury and consequent IgG loss, leading to CMV reactivation. Hence, cytokine inhibition represents a logical strategy to prevent endothelial injury, thereby preserving humoral immunity after immunotherapy.

3 August 2023 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
ASAshleigh P. Scott
Ashleigh P. Scott
AHAndrea S Henden
Andrea S Henden
GKGlen A. Kennedy
Glen A. Kennedy
STSiok-Keen Tey
Siok-Keen Tey
Acute gastrointestinal graft versus host disease (GI-GVHD) is a common complication following allogeneic haematopoietic cell transplantation (HCT), and is characterised by severe morbidity, frequent treatment-refractoriness, and high mortality. Early, accurate identification of GI-GVHD could allow for therapeutic interventions to ameliorate its severity, improve response rates and survival; however, standard endoscopic biopsy is inadequately informative in terms of diagnostic sensitivity or outcome prediction. In an era where rapid technological and laboratory advances have dramatically expanded our understanding of GI-GVHD biology and potential therapeutic targets, there is substantial scope for novel investigations that can precisely guide GI-GVHD management. In particular, the combination of tissue-based biomarker assessment (plasma cytokines, faecal microbiome) and molecular imaging by positron emission tomography (PET) offers the potential for non-invasive, real-time in vivo assessment of donor:recipient immune activity within the GI tract for GI-GVHD prediction or diagnosis. In this article, we review the evidence regarding GI-GVHD diagnosis, and examine the potential roles and translational opportunities posed by these novel diagnostic tools, with a focus on the evolving role of PET.